[Form 3] Pharvaris N.V. Initial Statement of Beneficial Ownership
Filing Impact
Filing Sentiment
Form Type
3
Rhea-AI Filing Summary
Pharvaris N.V. executive Dr. Anne Lesage, Chief Early Development, filed an initial Form 3 reporting her ownership in the company. She lists multiple stock option awards on common stock, including grants covering 60,000 shares at an exercise price of $28.0000 expiring on March 3, 2036 and other options with exercise prices ranging from $2.5900 to $22.3100. She also reports Common Stock holdings of 56,450 shares directly and 163,969 shares indirectly through GrayMatters Consulting B.V. Footnotes note outstanding restricted stock units from prior awards that settle in common shares with time-based vesting schedules.
Positive
- None.
Negative
- None.
Insider Trade Summary
9 transactions reported
Mixed
9 txns
Insider
Lesage Anne
Role
Chief Early Development
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 60,000 shares (Direct);
Common Stock — 56,450 shares (Direct);
Common Stock — 163,969 shares (Indirect, GRAYMATTERS CONSULTING BVBA)
Footnotes (1)
- Includes restricted stock units previously granted under the Company's equity plan that remain outstanding as of March 18, 2026. The awards settle in shares of common stock and are reported in Table I as non-derivative securities. Vesting occurs as follows: -20,000 RSUs from an award granted March 3, 2026 of which 25% will vest March 3, 2027 with the remainder vesting monthly thereafter; -15,000 RSUs from an award granted March 12, 2025 of which 25% vested March 12, 2026 with the remainder vesting monthly thereafter; -8,568 RSUs from an award granted April 11, 2024 of which 25% vested April 11, 2025 with the remainder vesting monthly thereafter. GrayMatters Consulting B.V., an entity controlled by Dr. Lesage. 25% of the option will vest on March 3, 2027 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on March 12, 2026 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 11, 2025 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 6, 2024 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on April 1, 2023 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on February 5, 2022 with the remaining shares vesting in 1/48 monthly installments thereafter. 25% of the option vested on January 1, 2021 with the remaining shares vesting in 1/48 monthly installments thereafter.
